Treatment of Multicentric Castleman's Disease PDF Print E-mail
Written by Stanford University   
Wednesday, 07 July 2004 09:54
Treatment of multicentric Castleman's disease complicated by the development of non-Hodgkin's lymphoma with high-dose chemotherapy and autologous peripheral stem-cell support.
Advani R, Warnke R, Rosenberg S

Stanford University School of Medicine, Division of Oncology, CA, USA.

BACKGROUND: Castleman's disease or angiofollicular lymph node hyperplasia is a rare entity with a localized/unicentric or a generalized/multicentric presentation. While surgery is curable for most localized presentations, there is limited information regarding the optimal management of the multicentric type. The latter type is associated with a poor prognoses and can be associated with the development of lymphoma and infections. PATIENTS AND METHODS: In this report we describe a case of multicentric Castleman's disease who failed steroids and chemotherapy and developed a follicular mixed lymphoma. He was treated with high-dose chemotherapy with autologous stem-cell support and remains disease at four years of follow-up. CONCLUSIONS: A long-term durable remission may be possible with high dose chemotherapy with stem-cell support. This treatment modality should be considered an option in the management of multicentric Castleman's disease.

Ann Oncol 1999 Oct;10(10):1207-9
Last Updated on Tuesday, 11 November 2008 04:00